While most Japanese pharma companies were shedding capital value by as much as 7% today, Mitsubishi Chemical (TYO: 4188) closed up 3.48% at 625 yen on the news that one of its units had developed a vaccine against the novel coronavirus.
Canada-based biotech firm Medicago, a subsidiary of Mitsubishi Tanabe Pharma, on Thursday announced it had successfully produced a virus-like particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene.
Production of the VLP is the first step in developing a vaccine for COVID-19 which will now undergo pre-clinical testing for safety and efficacy. Once this is completed, Medicago expects to discuss with the appropriate health agencies to initiate human trials of the vaccine by summer (July/August) 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze